February 2006
Worldwide Biotech;Feb2006, Vol. 18 Issue 2, p1
Trade Publication
Reports that Sanofi-Aventis and Regeron Pharmaceuticals Inc. have expanded their Vascular Endothelial Growth Factor (VEGF) Trap collaboration agreement to include Japan. Joint development and commercialization of the VEGF Trap throughout the world; Remuneration for the inclusion of Japan into the VEGF Trap collaboration; Clinical information on VEGF.


Related Articles

  • In the news….  // Hudson Valley Business Journal;1/9/2006, Vol. 17 Issue 1, p8 

    The article offers news briefs related to the field of business. The UBS/Gallup Index of Investor Optimism indicates an increase in investor optimism in December over November. Over the past seven years, December index has been higher than November index. This suggests an increase in optimism...

  • SANOFI-AVENTIS/REGENERON EXPAND VEGF TRAP PACT TO JAPAN.  // Worldwide Videotex Update;Feb2006, Vol. 25 Issue 2, p117 

    The article reports on the changes made to the Vascular Endothelial Growth Factor (VEGF) Trap collaboration agreement by Sanofi-Aventis and Regeneron Pharmaceuticals Inc. Sanofi-Aventis will pay 100% of VEGF Trap development expenses under the collaboration agreement. The role of VEGF is to...

  • Regeneron, Sanofi-Aventis Start Two Phase III Aflibercept Trials. Morrison, Trista // BioWorld Today;8/24/2007, Vol. 18 Issue 165, p1 

    The article reports that the Phase III trials with aflibercept or VEGF Trap in prostate cancer and non-small cell lung cancer (NSCLC) were initiated by Regeneron Pharmaceuticals Inc. and partner Sanofi-Aventis Group. Chief Scientific Officer of Regeneron, George Yancopoulos, said that the major...

  • Regeneron, Sanofi Pull the Plug on Aflibercept Pancreatic Trial.  // BioWorld Today;9/14/2009, Vol. 20 Issue 176, p1 

    This article reports on the decision of Regeneron Pharmaceuticals Inc. and partner Sanofi-aventis Group to discontinue their Phase III trial of aflibercept plus gemcitabine versus placebo plus gemcitabine for the first-line therapy of metastatic pancreatic cancer. According to an independent...

  • EARNINGS ROUNDUP.  // BioWorld Today;8/5/2009, Vol. 20 Issue 149, p7 

    The article reports on the earnings of Regeneron Pharmaceuticals Inc. for the second quarter of 2009. Regeneron had total revenue of 90 million dollars, which includes revenue of 4.5 million dollars in net sales of Arcalyst, an interleukin-1 blocker approved for cryopyrin-associated period...

  • Sanofi, Regeneron Cozying Up: More Antibody Cash Long Term. Osborne, Randy // BioWorld Today;11/11/2009, Vol. 20 Issue 218, p1 

    The article reports on the expansion of a deal between pharmaceutical companies Sanofi-Aventis and Regeneron Pharmaceuticals Inc. that would add five years to the arrangement. As part of the new terms of the deal, Sanofi will increase its funding from 100 million U.S. dollars to 160 million U.S....

  • CVS' Amgen Pick 'Raises The Bar' For Regeneron, Sanofi. ELAINE LOW // Investors Business Daily;11/23/2015, p00 

    The article focuses on the coverage of cholesterol drug Repatha from Amgen by health care company CVS Health. It states that the CVS Health's coverage of Repatha put pressure on Regeneron and Sanofi, makers of cholesterol drug Praluent. Comments from CVS chief medical officer Troyen Brennan and...

  • Aflibercept: Bimonthly intravitreal injection for AMD. Tanzi, Maria G. // Pharmacy Today;Feb2012, Vol. 18 Issue 2, p43 

    The article evaluates the Eylea, a vascular endothelial growth factor (VEGF) inhibitor indicated for age-related macular degeneration, from Regeneron Pharmaceuticals Inc.

  • 2-month dosing of aflibercept proves as effective as 1-month dosing of ranibizumab for wet AMD.  // Ocular Surgery News Europe;Jan2012, Vol. 23 Issue 1, p17 

    The article discusses a study on the efficacy of the Vascular Endothelial Growth Factor (VEGF) Trap-Eye aflibercept ophthalmic solution from Regeneron Pharmaceuticals and Bayer HealthCare in the treatment of neovascular age-related macular degeneration.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics